Benzofuran-2-Carboxylic Acid Derivatives: Potent PTPRO Inhibitors for IBD Treatment

Xiao Liang published a dataset on figshare in 2026 describing benzofuran-2-carboxylic acid derivatives as PTPRO inhibitors for inflammatory bowel disease. The data likely contains results from screening and structure-guided optimization, yielding compounds with specific IC50 values like 0.54 μM and 0.16 μM. The dataset is 5.3 KB in size and is available in CSV format.

Use Cases

• Structure-activity relationship analysis based on the described benzofuran-2-carboxylic acid derivative library.
• Potency screening for PTPRO inhibitors based on the reported IC50 values for compounds 10j and 30k.
• In vivo efficacy modeling for colitis treatment based on the described murine DSS-induced colitis model results.
• Pharmacokinetic property prediction based on the mention of favorable oral bioavailability for the lead compound.

Strengths

• Includes specific potency metrics, such as an IC50 of 0.54 μM for compound 10j and 0.16 μM for compound 30k.
• Describes in vivo validation in a murine DSS-induced colitis model, indicating experimental relevance.
• Dataset is small (5.3 KB), facilitating quick download and initial inspection.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for statistical modeling.
• Data may reflect experimental bias inherent to the specific in vitro and murine models described.

Provenance

Source

Xiao Liang via figshare.

Collection Method

Likely contains results from chemical library screening and structure-guided optimization of synthetic compounds.

Freshness

Last updated 2026-04-28 05:05:34; freshness should be verified.